Question-and-Answer Session
Operator
Thank you. (Operator instructions) Your first question comes from Derek Jellinek.
Derek Jellinek – Susquehanna Financial Group
Great. Thanks for taking my question, guys. A couple questions. On 4665, can you maybe talk about the current ongoing trial in ITP, the enrollment that is? When do we expect data there? And given that it’s a 24-patient study, do you think we'll have enough numbers once that report is out to potentially peak partner interest? That's the first question.
John Higgins
Yes, okay. So, maybe we'll address those questions. So, Derek, I'll give you a little more color on the status of that study. We generally don't report the specific numbers in terms of enrollment in terms of having a regular minute-by-minute update. I will say that out of 24 patients, we have not enrolled even half of the patients yet. We just started the study in April. We have just in the last six weeks or so brought most of the centers online. As you know, it’s kind of a staggered effect, as you bring the centers online. And then there is a period of screening of patients and so on. We screen quite a few patients. We've got strict enrollment criteria. Patients are enrolled. A few patients, in fact, have completed the six weeks of treatment. As far as having data, it is too hard to predict when the study will be finished. We would like to be able to have interim data at least at ASH at the end of 2008. We think that is doable at this time. But we are going to continue focusing on getting the patients enrolled. As far as will this study be adequately powered to give us some further evidence of activity in sick patients, we absolutely believe it is. You never know until the study is finished, but the drug activity in healthy volunteers is very clear. We're measuring platelets, which is a clean, discreet end point. And we do believe since it is only one treatment dosing group that that sample size will be large enough to show meaningful differences between drug and placebo.
Derek Jellinek – Susquehanna Financial Group
Great. Thanks for that. And on 4665, the other clinical study, can we talk about, John, the gating factors currently to commencing the MDS study and when will we really see the start of the HCV study?
John Higgins
- To read the full transcript on Seeking Alpha, click here »
